Estuary debuts with $103M to develop kidney disease gene therapies
Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. The company’s cash comes from a ...
Wayne Sackett, Estuary Biotherapeutics CEO October 16, 2026 06:30 AM EDT FinancingCell/Gene Tx Estuary debuts with $103M to develop kidney disease gene therapies Ayisha Sharma News Reporter Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that